Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients With Rheumatoid Arthritis Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function,
health-related quality of life (HRQOL) and fatigue.
Source: www.medicalnewstoday.comNanoBio Demonstrates New Topical Approach To Treating Nail Fungus That Circumvents Problems With Current Therapy A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the entire nail plate, according to a study conducted by NanoBio Corporation.
Source: www.medicalnewstoday.comDrug Information Association Conference To Explore Global Pharmacovigilance And Risk Management Strategies And Regultory Frameworks The field of medical product safety continues to grow in complexity, with both clinical trial safety and post-marketing pharmacovigilance becoming ever more critical in the development and marketed use of medical products. In response, the Drug Information Association (DIA) will host
Source: www.medicalnewstoday.comNew Data Show In Vitro Potency Of Doripenem Against Resistant Bacteria Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced new study results that demonstrate doripenem (DORIBAX(TM), doripenem for injection), a carbapenem antibiotic, was found to be more potent in vitro against certain strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases (ESBLs) than other commonly used carbapenems.
Source: www.medicalnewstoday.comLong-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir As Part Of HIV Combination Therapy In Treatment-Naive Adults Ninety-six week results presented from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (two 400 mg tablets) with 100 mg ritonavir (r) once daily reached an undetectable viral load (
Source: www.medicalnewstoday.comRecommendation By Researchers To Strengthen Restrictions On Off-Label Promotion By Pharmaceutical Companies Researchers are asking for tougher penalties and fines for pharmaceutical companies that market
drugs for "off label" promotion, according to a study published in the October 28 issue of the open access journal PLoS
Medicine. New regulations are needed to address this practice, say Adriane Fugh-Berman, M.D., an associate professor in the GUMC Department of Physiology and Biophysics, and Douglas Melnick, M.D.
Source: www.medicalnewstoday.comNuvo Research Presents Positive Phase III Study Results For Pennsaid At Leading Rheumatology Conference Nuvo Research Inc.
Source: www.medicalnewstoday.comU.S. Consumers Place More Importance On Price And Value When Choosing Over-the-Counter Products Compared To Global Consumers An added sign of a battered U.S. economy, U.S. consumers place more importance on price and value when choosing over-the-counter (OTC) medication compared to global consumers, according to a global online survey conducted by The Nielsen Company in partnership with the Association of the European Self-Medication Industry (AESGP). Thirty percent of U.S. consumers consider price important when choosing OTC products, while on average, only 17 percent of global consumers do.
Source: www.medicalnewstoday.comTrubion Reports Re-treatment Results Following Phase 1/2a And Phase 2b Studies Evaluating TRU-015 For Rheumatoid Arthritis Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced positive data from a Phase 1/2a study demonstrating that repeat administration with TRU-015 continues to produce persistent responses and significant improvements in rheumatoid arthritis (RA) signs and symptoms based on American College of Rheumatology (ACR) criteria.
Source: www.medicalnewstoday.comVertex Pharmaceuticals Highlights HCV - Telaprevir Development Program Phase 3 Development in Treatment-Naïve Population - Vertex and Tibotec have completed enrollment in the global 3-arm pivotal Phase 3 ADVANCE trial that is focused on 24-week telaprevir-based response-guided regimens. In the ADVANCE study, telaprevir is being dosed for 8 or 12 weeks. Vertex expects to have sustained viral response (SVR) data from the study in the first half of 2010.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 PM
